Volume 133, Issue 5, Pages 1437-1444 (November 2007) Entecavir Therapy for up to 96 Weeks in Patients With HBeAg-Positive Chronic Hepatitis B  Robert G. Gish, Anna S. Lok, Ting–Tsung Chang, Robert A. de Man, Adrian Gadano, José Sollano, Kwang–Hyub Han, You–Chen Chao, Shou–Dong Lee, Melissa Harris, Joanna Yang, Richard Colonno, Helena Brett–Smith  Gastroenterology  Volume 133, Issue 5, Pages 1437-1444 (November 2007) DOI: 10.1053/j.gastro.2007.08.025 Copyright © 2007 AGA Institute Terms and Conditions

Figure 1 Study design and protocol-defined outcomes through 96 weeks. Patients entered the second year of treatment at week 52, based on the results of week 48 HBV DNA by bDNA assay and HBeAg status. ETV, entecavir; LVD, lamivudine; R, responder (HBV DNA level <0.7 MEq/mL and HBeAg negative); VR, virologic responder (HBV DNA level <0.7 MEq/mL and HBeAg positive); NR, nonresponder (HBV DNA level ≥0.7 MEq/mL). Only VRs were to continue blinded therapy into the second year. Gastroenterology 2007 133, 1437-1444DOI: (10.1053/j.gastro.2007.08.025) Copyright © 2007 AGA Institute Terms and Conditions

Figure 2 Distribution of HBV DNA levels through week 96 in the second-year treatment cohort (entecavir [ETV], 243; lamivudine [LVD], 164). Circle diameters are proportional to the percent of patients at the specified HBV DNA level, with the circles in each column totaling 100%. EOD (end of dosing) is defined as the last observation on-treatment. Gastroenterology 2007 133, 1437-1444DOI: (10.1053/j.gastro.2007.08.025) Copyright © 2007 AGA Institute Terms and Conditions